Merck & Co Inc (NYSE: MRK) will stop for futility the Phase 3 LYNK-003 trial of Lynparza with or without bevacizumab for unresectable or metastatic colorectal cancer who have not progressed following first-line induction.
The action follows the recommendation of an independent Data Monitoring Committee (DMC) after the DMC reviewed the data from a planned interim analysis.
Lynparza is a PARP inhibitor co-developed and co-commercialized with AstraZeneca Plc (NASDAQ: AZN).
At the pre-specified interim analysis for progression-free survival, the efficacy of Lynparza as a monotherapy and in combination with bevacizumab relative to control met the criteria for futility. Both experimental arms will be discontinued.
No new safety signals were observed with Lynparza in the 309-subject trial.
Price Action: MRK shares are up 0.06% at $92.40, and AZN shares are up 2.55% at $68.06 during the market session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.